Ventricular tachycardia
Drug research and approvals for ventricular tachycardia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 87 studies of ventricular tachycardia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 2 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 87
- Trials authorized in Canada: 4
- FDA orphan approvals: 2
- EU medicines: 0
- CArdiac STereotactic Radiation Treatment for Ablation of ventRicular TachycardiaNCT07931014 · Not applicable · Cancer Research Antwerp · starts Feb 25, 2026
- AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)NCT07859020 · Not reported · Inha University Hospital · starts Dec 1, 2023
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- SPIKE FLOW Endocardial Lead Safety and Performance StudyNCT07820072 · Not applicable · FIAB SpA · starts Aug 7, 2026
- Targeted Ablation to Isolate Scar Channels Causing Ventricular TachycardiaNCT07814079 · Not reported · New York Medical College · starts Mar 27, 2025
- Predict Arrhythmia Risk Using Intelligent SoftwareNCT07792694 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jan 1, 2023
- Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex AblationNCT07777744 · Not reported · University Hospital, Basel, Switzerland · starts Jul 1, 2024
- Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular TachycardiaNCT07759427 · Not applicable · University of Warwick · starts Aug 15, 2026
- Evaluation of the DuoVT PFA System for Ventricular TachycardiaNCT07706712 · Not applicable · Abbott Medical Devices · starts Sep 29, 2026
Approved 2
- AmiodaroneHERG blocker
- ZiprasidoneSerotonin 2a (5-HT2a) receptor antagonist
Phase 2 5
- DantroleneRyanodine receptor 1 antagonist
- MetoprololBeta-1 adrenergic receptor antagonist
- EpinephrineAdrenergic receptor agonist
- Celivarone
- Alcohol
Phase 1 or earlier 2
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Fish oil triglyceridesSupplement
How its trials ended
389 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 101 whose ending is known, 39% met their primary endpoint, 2% missed it and 59% stopped early.
- Completed, result not reported13033%
- Ongoing10226%
- Status unknown5614%
- Met its primary endpoint3910%
- Stopped: other or unclear287%
- Stopped: enrollment or feasibility185%
- Stopped: sponsor or business decision82%
- Stopped: lack of efficacy41%
- Missed its primary endpoint21%
- Stopped: funding21%
| Jun 27, 2025 | A phase 1b, multicenter, open-label, dose finding study to investigate the safety and tolerability of a single intravenous dose of SGT-501 in patients with…SGT-501 (RAAV8-DES-CASQ2) | Solid Biosciences | Pending |
| Dec 18, 2024 | A phase 2, double-blind, repeat-dose, placebo-controlled crossover study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…CRD-4730 | Cardurion Pharmaceuticals | Ongoing |
| Dec 2, 2022 | A phase 2a, investigator and subject blinded, sponsor unblinded, placebo-controlled, clinical study to evaluate the safety, tolerability, pharmacokinetics, and…CRD-4730 | Cardurion Pharmaceuticals | Closed |
| Jul 5, 2018 | Pretreatment with atropine to reduce exercise-triggered ventricular ectopy in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT)Atropine | BC CHILDREN's HOSPITAL HEART CENTRE | Pending |
| Jul 2, 2009 | So-AqueousFor use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of… | AltaThera Pharmaceuticals LLC | Approved |
| Aug 3, 1995 | CordaroneFor initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular… | Wyeth-Ayerst Laboratories | Approved |
| Mar 30, 2026 | (S)-(3-bromo-4-(trifluoromethyl)phenyl)(2-(5-methyl-[1,2,4]t…Treatment of catecholaminergic polymorphic ventricular tachycardia | Agiana Pharmaceuticals | Designated |
| May 5, 2020 | 4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl…Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia | RyCarma Therapeutics, Inc. | Designated |
| Oct 2, 2014 | Adeno-associated viral vector serotype 8 containing the…Treatment of catecholaminergic polymorphic ventricular tachycardia | Solid Biosciences Inc. | Designated |
| Aug 17, 1993 | AmiodaroneTreatment of incessant ventricular tachycardia. | Academic Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA